Hypothesis

Individuals carrying the PER3^5/5 genotype experience greater circadian misalignment and metabolic risk when exposed to suboptimal morning light spectra; a tailored dawn‑light intervention that matches their ipRGC sensitivity (peak ~480 nm) and intensity (≈500 lux for 30 min) will reset hepatic clock gene expression (Bmal1, Per2, Cry1) and improve glucose tolerance within two weeks.

Rationale

Morning blue‑light (460–480 nm) activates ipRGCs, driving SCN phase advances [https://pubmed.ncbi.nlm.nih.gov/41591657/]. Mathematical modeling shows that for low‑irradiance exposures, longer wavelengths (≈555 nm) can be more effective, whereas higher intensities favor short‑wavelength light [https://pmc.ncbi.nlm.nih.gov/articles/PMC4414925/], [https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0251478]. PER3 variants modulate sleep homeostasis and light‑induced melatonin suppression [https://www.chronobiologyinmedicine.org/m/journal/view.php?number=167], [https://pmc.ncbi.nlm.nih.gov/articles/PMC4734149/]. Emerging data link circadian disruption to hepatic glucose metabolism, suggesting that mistimed light cues impair peripheral clocks independent of the SCN [https://www.cdc.gov/niosh/work-hour-training-for-nurses/longhours/mod2/20.html].

We propose that PER3^5/5 carriers have a higher ipRGC activation threshold, requiring either increased intensity or a shift toward the spectral peak that maximizes melanopsin efficacy. Delivering a personalized dawn‑light protocol should therefore produce larger phase advances and stronger entrainment of hepatic oscillators than a uniform bright‑light regimen.

Experimental Design

• Participants: 60 healthy adults, stratified by PER3 genotype (PER3^4/4 vs PER3^5/5), balanced for sex and age (20‑35 y).
• Intervention (2 weeks):
  • Personalized group: 30 min of LED dawn light at 500 lux, peak wavelength 480 nm, delivered 30 min before habitual wake time.
  • Control group: 30 min of broad‑spectrum white light at 500 lux (peak ~560 nm) same timing.
• Outcomes:
  1. Primary: Dim‑light melatonin onset (DLMO) shift (salivary melatonin) measured weekly.
  2. Secondary: Hepatic clock gene expression in peripheral blood monocytes (qPCR for Bmal1, Per2, Cry1) at baseline and endpoint.
  3. Exploratory: Oral glucose tolerance test (OGTT) AUC, fasting insulin, and triglycerides.
• Analysis: Mixed‑effects model with genotype, light condition, and time as fixed effects; participant as random effect. Interaction term tests whether PER3^5/5 individuals show greater DLMO advancement and hepatic clock normalization under personalized light versus control.

Falsifiability

If PER3^5/5 participants do not exhibit a significantly larger DLMO shift (≥15 min) or greater improvement in hepatic clock gene expression and OGTT metrics compared with PER3^4/4 peers under the personalized condition, the hypothesis is refuted. Conversely, a significant genotype‑by‑light interaction supporting enhanced metabolic outcomes would confirm the mechanistic link between ipRGC‑mediated light perception, PER3‑dependent sensitivity, and peripheral circadian‑metabolic coupling.

Potential Impact

Validating this approach would enable precision chronotherapies that optimize light spectra and intensity based on genetic risk, reducing circadian‑related metabolic disease burden.